Duh, really?
Several directors [of CIRM] have noted in the past that it is companies that most directly bring therapies to the marketplace – not academic institutions.
CIRM still flounders with a poorly-defined intellectual property policy, and recently engaged an attorney, not registered before the USPTO, to advise on IP matters.
Somewhat like Charlie on the MTA, CIRM will likely never return a dime to California taxpayers from patent royalties:
Did he ever return,
No he never returned
And his fate is still unlearn'd
0 Comments:
Post a Comment
<< Home